Hyperparathyroidism – A Complete Patient‑Friendly Guide

Overview

Hyperparathyroidism is a condition in which one or more of the four parathyroid glands produce too much parathyroid hormone (PTH). PTH regulates calcium and phosphorus balance; excess hormone drives calcium out of bones and into the bloodstream, leading to a range of systemic effects.

• Primary hyperparathyroidism (PHPT): the gland itself is overactive, usually due to a benign adenoma (≈80% of cases), hyperplasia, or, rarely, cancer.
• Secondary hyperparathyroidism: the glands react to low calcium levels, most often from chronic kidney disease or severe vitamin D deficiency.
• Tertiary hyperparathyroidism: longstanding secondary hyperparathyroidism causes autonomous gland function even after the original trigger is treated.

The disorder is most common in adults over 50 and affects women about three times more often than men. In the United States, an estimated 1 % of post‑menopausal women and 0.1 % of men have overt primary hyperparathyroidism, though many are asymptomatic and discovered incidentally on routine calcium testing.^{[1] Mayo Clinic}

Symptoms

Symptoms vary widely; some patients have no complaints, while others experience multiple systems being affected. Below is a comprehensive list with brief explanations.

Bone‑related symptoms

• Bone pain – aching pain, often in the hips, ribs, or pelvis.
• Fractures – especially of the forearm (Colles fracture) or vertebrae, occurring with minimal trauma.
• Osteitis fibrosa cystica (brown tumors) – rare, cyst‑like bone lesions that can cause swelling.
• Loss of height – due to vertebral compression fractures.

Kidney‑related symptoms

• Kidney stones – calcium‑oxalate stones are the classic presentation.
• Frequent urination and polyuria – high calcium interferes with renal concentrating ability.
• Nephrocalcinosis – calcium deposits within the kidney tissue, potentially reducing function.

Gastrointestinal symptoms

• Abdominal pain, nausea, vomiting.
• Peptic ulcer disease – hypercalcemia can increase gastric acid secretion.
• Constipation – calcium slows gut motility.

Neuro‑muscular symptoms

• Fatigue, weakness, or muscle aches.
• Depression, irritability, or anxiety – linked to calcium’s effect on neurotransmission.
• Memory problems or “brain fog”.

Cardiovascular symptoms

• High blood pressure – observed in up to 30 % of patients.
• Palpitations or arrhythmias – severe hypercalcemia can disturb cardiac conduction.

General signs

• Elevated serum calcium (usually >10.5 mg/dL).
• Elevated alkaline phosphatase due to bone turnover.
• Kidney function changes (elevated creatinine).

Causes and Risk Factors

Primary hyperparathyroidism

• Parathyroid adenoma (single benign tumor) – the leading cause.
• Parathyroid hyperplasia – enlargement of 2‑4 glands.
• Parathyroid carcinoma – very rare (<1 %).
• Genetic syndromes – MEN1, MEN2A, and familial isolated hyperparathyroidism increase risk.

Secondary hyperparathyroidism

• Chronic kidney disease (CKD) – reduced activation of vitamin D and phosphate retention.
• Severe vitamin D deficiency.
• Malabsorption syndromes (e.g., celiac disease, bariatric surgery).
• Prolonged use of certain medications (e.g., loop diuretics, phosphate binders).

Risk factors

• Age > 50 years.
• Female sex (particularly post‑menopausal).
• Family history of hyperparathyroidism or MEN syndromes.
• History of radiation to the head/neck (rare).
• Long‑standing kidney disease.

Diagnosis

Diagnosis rests on a combination of biochemical testing, imaging, and sometimes genetic evaluation.

Laboratory tests

• Serum calcium (total or ionized) – elevated in 90 % of primary cases.
• Parathyroid hormone (PTH) level – inappropriately normal or high when calcium is high.
• Serum phosphate – often low in primary hyperparathyroidism.
• 25‑hydroxy vitamin D – to rule out deficiency as a cause of secondary disease.
• Creatinine & eGFR – to assess kidney function.
• 24‑hour urinary calcium – helps differentiate primary from familial hypocalciuric hypercalcemia.

Imaging studies

• Neck ultrasound – first‑line, non‑invasive, can locate enlarged glands.
• Sestamibi scan (Tc‑99m sestamibi) – nuclear medicine test that highlights hyperfunctioning tissue; sensitivity ≈85‑90 %.
• 4‑D CT – provides detailed anatomic info, useful when prior imaging is inconclusive.
• Bone density (DEXA) scan – assesses osteoporosis, present in up to 30 % of patients.
• Kidney imaging (ultrasound or CT) – evaluates for stones or nephrocalcinosis.

Genetic testing (when indicated)

If there is a family history of endocrine tumors or young onset (<30 y), testing for MEN1, CDC73 (HRPT2), or other relevant genes is recommended per NCCN guidelines.^{[2] NCCN}

Treatment Options

Treatment decisions are individualized based on calcium level, symptom burden, bone density, kidney involvement, age, and surgical risk.

When surgery is indicated

• Serum calcium >1 mg/dL above the upper limit of normal.
• Evidence of osteoporosis (T‑score ≤ –2.5) or fractures.
• Kidney stones or reduced kidney function.
• Symptomatic patients (bone pain, neuro‑cognitive symptoms).
• Younger patients (<50 y) even if asymptomatic, because of long‑term risk.

Parathyroidectomy

The definitive treatment for primary hyperparathyroidism.

• Minimally invasive parathyroidectomy (MIP) – guided by pre‑operative imaging; 95 % cure rate.
• Bilateral neck exploration – used when imaging is negative or multigland disease is suspected.
• Intra‑operative PTH monitoring (IoPTH) confirms removal of the hyper‑secreting tissue.

Medical management

Reserved for patients who cannot undergo surgery or have mild disease.

• Calcimimetics (e.g., cinacalcet) – increase the sensitivity of calcium‑sensing receptors, lowering PTH and calcium. Effective in secondary and tertiary hyperparathyroidism.
• Bisphosphonates (e.g., alendronate) – reduce bone resorption while awaiting surgery.
• Denosumab – a RANKL inhibitor useful for severe osteoporosis when bisphosphonates are contraindicated.
• Vitamin D supplementation – correct deficiency; caution to avoid hypercalcemia.
• Hydration & low‑oxalate diet – help prevent kidney stones.

Lifestyle and supportive measures

• Stay well‑hydrated (≥2 L water/day) to dilute urinary calcium.
• Limit calcium‑rich supplements unless prescribed.
• Moderate sodium intake – excess sodium promotes calcium loss.
• Regular weight‑bearing exercise to support bone health.

Living with Hyperparathyroidism

Monitoring

• Serum calcium and PTH every 6‑12 months if not operated.
• DEXA scan every 1–2 years to track bone density.
• Annual renal ultrasound if history of stones.

Dietary tips

• Focus on fruits, vegetables, whole grains, and lean protein.
• Limit high‑oxalate foods (spinach, rhubarb, nuts) if prone to stones.
• Consume adequate magnesium (nuts, seeds) – may help regulate calcium.

Physical activity

• Weight‑bearing activities (walking, jogging, resistance training) 3–5 times/week.
• Balance and flexibility exercises to reduce fall risk.

Psychological well‑being

Fatigue and mood changes are common. Consider counseling, stress‑reduction techniques, and discuss any persistent depressive symptoms with a mental‑health professional.

Medication adherence

If you’re on cinacalcet, bisphosphonates, or vitamin D, set daily reminders and keep a medication list for your healthcare team.

Prevention

Primary hyperparathyroidism cannot be prevented in most cases because it often arises from sporadic adenomas. However, secondary forms can be mitigated:

• Maintain optimal vitamin D levels (screen high‑risk groups).
• Manage chronic kidney disease aggressively – control blood pressure, limit phosphorus intake, and use phosphate binders as directed.
• Avoid excessive calcium supplementation unless medically indicated.
• Regular health check‑ups for individuals with a family history of MEN syndromes.

Complications

If left untreated, prolonged hyperparathyroidism can lead to:

• Osteoporosis & fractures – up to 30 % develop significant bone loss.
• Nephrolithiasis – recurrent stones may cause chronic kidney disease.
• Nephrocalcinosis – calcium deposition within renal parenchyma.
• Cardiovascular disease – hypertension, left ventricular hypertrophy, and increased risk of coronary artery disease.
• Neuro‑cognitive impairment – memory deficits and decreased quality of life.
• Pancreatitis – rare, but hypercalcemia is a recognized trigger.

When to Seek Emergency Care

References

1. Mayo Clinic. Primary hyperparathyroidism. Updated 2023. https://www.mayoclinic.org/…
2. National Comprehensive Cancer Network (NCCN). Genetic testing for endocrine tumors. Version 2.2024. https://www.nccn.org/…
3. National Institutes of Health (NIH). Hypercalcemia emergency management. 2022. https://www.ncbi.nlm.nih.gov/…
4. American Association of Endocrine Surgeons. Guidelines for the surgical management of primary hyperparathyroidism. 2023. https://www.endocrinesurgeons.org/…
5. Cleveland Clinic. Hyperparathyroidism – Symptoms, Diagnosis, Treatment. 2024. https://my.clevelandclinic.org/…